Last reviewed · How we verify
Intuniv
At a glance
| Generic name | Intuniv |
|---|---|
| Also known as | Extended release Guanfacine |
| Sponsor | New York State Psychiatric Institute |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression (PHASE2)
- Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders (PHASE2)
- Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study (PHASE2)
- Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS) (PHASE2)
- Treating Young Children With Attention Deficit Hyperactivity Disorder (PHASE4)
- Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH) (NA)
- Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance (PHASE4)
- AWARE: Management of ADHD in Autism Spectrum Disorder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intuniv CI brief — competitive landscape report
- Intuniv updates RSS · CI watch RSS
- New York State Psychiatric Institute portfolio CI